$MDxHealth (MDXH.US)$ MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance Monday, 13th January at 5:00 am MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance IRVINE, CA – January 13, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 reve...
$SPDR S&P Biotech ETF (XBI.US)$ The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023. As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
MDxHealth Stock Forum
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance
Monday, 13th January at 5:00 am
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues
and Issues 2025 Revenue Guidance
IRVINE, CA – January 13, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 reve...
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
$Mullen Automotive (MULN.US)$ $MDxHealth (MDXH.US)$
ALERTS still active - at/near average WINT BBBY ADTX CFRX MDXH
$Getaround (GETR.US)$ $Petros Pharmaceuticals (PTPI.US)$ $Augmedix (AUGX.US)$ $Windtree Therapeutics (WINT.US)$ $Bed Bath & Beyond Inc (BBBY.US)$ $Aditxt (ADTX.US)$ $ContraFect (CFRX.US)$ $MDxHealth (MDXH.US)$
No comment yet